{"id":"https://openalex.org/W4310106090","doi":"https://doi.org/10.1182/blood-2022-162253","title":"Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)","display_name":"Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310106090","doi":"https://doi.org/10.1182/blood-2022-162253"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-162253","doi":"https://doi.org/10.1182/blood-2022-162253","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-162253","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041561013","display_name":"Dan T. Vogl","orcid":"https://orcid.org/0000-0002-2935-2566","observed_orcids":["https://orcid.org/0000-0002-2935-2566"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dan T. Vogl","raw_affiliation_strings":["1Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042487436","display_name":"Shebli Atrash","orcid":"https://orcid.org/0000-0003-4547-7534","observed_orcids":["https://orcid.org/0000-0003-4547-7534"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shebli Atrash","raw_affiliation_strings":["2Levine Cancer Institute, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Levine Cancer Institute, Charlotte, NC","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005732386","display_name":"Sarah A. Holstein","orcid":"https://orcid.org/0000-0002-9342-5635","observed_orcids":["https://orcid.org/0000-0002-9342-5635"]},"institutions":[{"id":"https://openalex.org/I1307117695","display_name":"Nebraska Medical Center","ror":"https://ror.org/03azxga02","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1307117695"]},{"id":"https://openalex.org/I59130452","display_name":"University of Nebraska Medical Center","ror":"https://ror.org/00thqtb16","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I59130452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah A. Holstein","raw_affiliation_strings":["3University of Nebraska Medical Center, Omaha, NE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3University of Nebraska Medical Center, Omaha, NE","institution_ids":["https://openalex.org/I1307117695","https://openalex.org/I59130452"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052163068","display_name":"Omar Nadeem","orcid":"https://orcid.org/0000-0002-4124-4277","observed_orcids":["https://orcid.org/0000-0002-4124-4277"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Omar Nadeem","raw_affiliation_strings":["4Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112786802","display_name":"Don M. Benson","orcid":"https://orcid.org/0000-0001-8837-0548","observed_orcids":["https://orcid.org/0000-0001-8837-0548"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]},{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Don M. Benson","raw_affiliation_strings":["5Ohio State University Comprehensive Cancer Center, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Ohio State University Comprehensive Cancer Center, Columbus, OH","institution_ids":["https://openalex.org/I2799885155","https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065131494","display_name":"Kaveri Suryanarayan","orcid":"https://orcid.org/0009-0002-8776-1533","observed_orcids":["https://orcid.org/0009-0002-8776-1533"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kaveri Suryanarayan","raw_affiliation_strings":["6Takeda Development Center Americas, Inc. (TDCA), Lexington, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Takeda Development Center Americas, Inc. (TDCA), Lexington, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009512812","display_name":"Yuyin Liu","orcid":"https://orcid.org/0000-0002-4995-832X","observed_orcids":["https://orcid.org/0000-0002-4995-832X","https://orcid.org/0000-0002-6450-6364"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yuyin Liu","raw_affiliation_strings":["6Takeda Development Center Americas, Inc. (TDCA), Lexington, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Takeda Development Center Americas, Inc. (TDCA), Lexington, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001458693","display_name":"Sabrina C. Collins","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sabrina Collins","raw_affiliation_strings":["6Takeda Development Center Americas, Inc. (TDCA), Lexington, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Takeda Development Center Americas, Inc. (TDCA), Lexington, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015775019","display_name":"Xavier Parot","orcid":"https://orcid.org/0009-0001-0250-3950","observed_orcids":["https://orcid.org/0009-0001-0250-3950"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xavier Parot","raw_affiliation_strings":["6Takeda Development Center Americas, Inc. (TDCA), Lexington, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Takeda Development Center Americas, Inc. (TDCA), Lexington, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077897003","display_name":"Jonathan L. Kaufman","orcid":"https://orcid.org/0000-0002-5687-6429","observed_orcids":["https://orcid.org/0000-0002-5687-6429"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan L. Kaufman","raw_affiliation_strings":["7Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I4390039307"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":1.7924,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.86834986,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":98},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"1357","last_page":"1359"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9129999876022339},{"id":"https://openalex.org/keywords/anti-cd38-monoclonal-antibody","display_name":"anti-CD38 monoclonal antibody","score":0.7490000128746033},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.7789999842643738},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.652999997138977},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6060000061988831},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.652999997138977},{"id":"https://openalex.org/keywords/immune-activation","display_name":"immune activation","score":0.3499999940395355},{"id":"https://openalex.org/keywords/myeloma-progression","display_name":"myeloma progression","score":0.3190000057220459}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6669872999191284},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.5560646057128906},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4656760096549988},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4576214551925659},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45682764053344727},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.43628615140914917},{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.41608908772468567},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39620184898376465},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3620728850364685},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.33347102999687195},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1160062849521637},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-162253","doi":"https://doi.org/10.1182/blood-2022-162253","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-162253","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3213443949","https://openalex.org/W4404995951","https://openalex.org/W4409785682","https://openalex.org/W4405040781","https://openalex.org/W4283389824","https://openalex.org/W4286295059","https://openalex.org/W4389222120","https://openalex.org/W7126121634","https://openalex.org/W4385702649","https://openalex.org/W4408021078"],"abstract_inverted_index":{"Introduction":[0],"Modakafusp":[1,682],"alfa":[2,683],"is":[3,185,679,742],"a":[4,52,179,247,322,333,378,517,557,685,690],"first-in-class,":[5],"immune-targeting,":[6],"attenuated":[7,13],"cytokine.":[8],"It":[9],"consists":[10],"of":[11,23,33,54,85,105,113,187,189,249,313,389,454,525,688,703,719],"2":[12,143,415,616,713],"interferon":[14],"(IFN)\u03b12b":[15],"molecules":[16],"genetically":[17],"fused":[18],"to":[19,35,110,321,446,663,715,725,732],"the":[20,79,86,196,240,304,308,341,408,439,665,734,738],"Fc":[21],"portion":[22],"an":[24,365],"anti-CD38":[25],"IgG4":[26],"monoclonal":[27],"antibody":[28],"(mAb),":[29],"allowing":[30],"targeted":[31],"delivery":[32],"IFN\u03b1":[34],"innate":[36],"and":[37,82,90,107,117,174,208,232,236,256,284,299,332,336,359,374,377,400,418,435,451,499,512,559,569,609,635,658,670,694,721,727,731],"adaptive":[38],"immune":[39,197,656,706],"cells,":[40],"as":[41,43,178,346],"well":[42],"myeloma":[44],"cells.":[45],"We":[46,76],"previously":[47],"reported":[48,296,355,382],"preliminary":[49],"results":[50,84],"from":[51],"cohort":[53],"30":[55,423],"pts":[56,273,280,286,391,406,424,508,538,545,571,617,623],"who":[57],"received":[58,101],"modakafusp":[59,124,314,393,427,548],"1.5":[60,175,209,428,473,549,578,626,699,726],"mg/kg":[61,172,176,206,210,319,348,358,361,372,385,395,410,429,474,550,579,627,700],"every":[62,142,148],"4":[63,622],"weeks":[64,144,150],"(Q4W)":[65],"in":[66,191,212,281,287,329,338,407,432,437,482,536,586,615],"this":[67],"phase":[68,712],"1/2":[69],"study":[70,87,714],"(NCT03215030)":[71],"(Kaufman":[72],"EHA":[73],"2022,":[74],"S181).":[75],"now":[77],"report":[78,524],"final":[80],"safety":[81,692],"efficacy":[83],"(parts":[88],"1":[89,330,339,419,513,523,554,560,638],"2),":[91],"including":[92,486,590],"minimal":[93],"residual":[94],"disease":[95],"(MRD)":[96],"status.":[97],"Methods":[98],"Pts":[99],"had":[100,274,398,402,416,420,509,516,556,562,572],"\u22653":[102],"prior":[103],"lines":[104],"treatment":[106],"were":[108,168,219,228,237,254,295,354,381,529],"refractory":[109],"or":[111,154],"intolerant":[112],"\u22651":[114,118],"proteasome":[115],"inhibitor":[116],"immunomodulatory":[119],"drug.":[120],"During":[121,290,350,387],"dose":[122,130,164,282,291,311,351,433,736],"escalation,":[123,165,292,352],"was":[125,161,315,343,368,441,448,456,465,566,640],"administered":[126],"intravenously":[127],"at":[128,170,204,230,233,246,317,625,633,642,698],"10":[129],"levels":[131,718],"between":[132,649,667],"0.001-6":[133],"mg/kg;":[134],"weekly":[135],"(QW;":[136],"cycles":[137],"1-2":[138],"only;":[139],"0.001-0.75":[140],"mg/kg),":[141,147,153],"(Q2W;":[145],"0.2-0.3":[146],"3":[149,325,347,401,405,506],"(Q3W;":[151],"0.4-0.75":[152],"Q4W":[155,177,211,305,430,551,580,628,730],"(0.75-6":[156],"mg/kg).":[157],"As":[158,182],"anti-myeloma":[159,696],"response":[160,447,455,575,669],"detected":[162],"during":[163],"expansion":[166,288],"cohorts":[167,203],"opened":[169],"0.4":[171,205,360,371,394,409],"Q3W":[173,207,411],"single":[180],"agent.":[181],"dexamethasone":[183],"(dex)":[184],"part":[186],"standard":[188],"care":[190],"MM,":[192],"but":[193],"could":[194],"counteract":[195],"activation":[198],"elicited":[199],"by":[200,263],"modakafusp,":[201],"additional":[202],"combination":[213],"with":[214,277,297,356,370,383,426,547,629,737],"40":[215],"mg":[216,723],"dex":[217,413],"QW":[218,298,362],"opened.":[220],"Bone":[221],"marrow":[222],"aspirates":[223],"(BMA)":[224],"for":[225,258,522],"MRD":[226,630],"evaluation":[227,662],"collected":[229,255,632],"screening":[231,634],"suspected":[234,636],"CR":[235,379],"assessed":[238],"utilizing":[239],"clonoSEQ\u00ae":[241],"next":[242],"generation":[243],"sequencing":[244],"assay":[245],"threshold":[248],"10-5.":[250,643],"Peripheral":[251],"blood":[252,655,705],"samples":[253,631],"evaluated":[257],"CD38":[259,650,671,708],"receptor":[260,651,672],"density":[261,652,673],"determination":[262],"flow":[264],"cytometry.":[265],"Results":[266],"At":[267,472,577],"data":[268],"cut-off":[269],"(April":[270],"2022),":[271],"100":[272],"been":[275],"treated":[276,425,546,624],"modakafusp;":[278],"56":[279],"escalation":[283,434],"44":[285],"cohorts.":[289],"dose-limiting":[293],"toxicities":[294],"Q2W":[300],"dosing":[301,306],"schedules.":[302],"In":[303],"schedule,":[307],"maximum":[309],"tolerated":[310],"(MTD)":[312],"exceeded":[316],"6":[318],"due":[320],"grade":[323],"(G)":[324],"infusion-related":[326],"reaction":[327],"(IRR)":[328],"pt":[331,515,555,561,565,639],"prolonged":[334],"thrombocytopenia":[335,493,591],"neutropenia":[337,487,610],"pt;":[340],"MTD":[342],"therefore":[344],"determined":[345],"Q4W.":[349,386],"PRs":[353,375],"0.1":[357],"(n=1":[363],"each),":[364],"unconfirmed":[366],"VGPR":[367,558],"observed":[369],"Q3W,":[373,396],"(n=3)":[376],"(n=1)":[380],"1.5-6":[384],"expansion,":[388],"8":[390,544],"receiving":[392],"5":[397,570],"SD":[399,417,563],"PD.":[403,421],"Of":[404,543,621],"+":[412,552,581],"cohort,":[414],"Among":[422],"(5":[431],"25":[436],"expansion),":[438],"ORR":[440],"43%":[442],"(Table),":[443],"median":[444,452],"time":[445],"1.2":[449],"months,":[450],"duration":[453],"not":[457,567],"reached":[458],"(range":[459],"1.0-18.9":[460],"months).":[461],"Median":[462],"progression-free":[463],"survival":[464],"5.7":[466],"months":[467],"(95%":[468],"confidence":[469],"interval":[470],"1.2-15.9).":[471],"Q4W,":[475,701],"G\u22653":[476,583],"treatment-emergent":[477],"adverse":[478],"events":[479],"(TEAEs)":[480],"occurred":[481,535,585,614],"26":[483],"(87%)":[484],"pts,":[485,589],"(n=19,":[488],"63%":[489],"[G4":[490,496,503,594,603],"n=9,":[491],"30%]),":[492],"(n=14,":[494],"47%":[495],"n=6,":[497],"20%]),":[498],"lymphopenia":[500,600],"(n=11,":[501],"37%":[502],"n=7,":[504],"23%]);":[505],"(10%)":[507],"G3":[510,518],"infections,":[511],"(3%)":[514],"bleeding":[519],"event.":[520],"Except":[521],"G4":[526,531],"hyperuricemia,":[527],"there":[528],"no":[530,573,647],"non-hematological":[532],"TEAEs;":[533],"IRRs":[534,613],"11":[537],"(37%":[539],"[G3":[540],"n=1,":[541,595,604],"3%]).":[542],"dex,":[553,582],"(1":[564],"evaluable":[568],"post-baseline":[574],"assessment).":[576],"TEAEs":[584],"7":[587],"(88%)":[588],"(n=4,":[592],"50%":[593],"13%]),":[596,605],"anemia":[597],"(n=2,":[598,601,607],"25%),":[599,608],"25%":[602],"pneumonia":[606],"(n=1,":[611],"13%).":[612],"(25%,":[618],"none":[619],"G\u22653).":[620],"CR,":[637],"MRD-":[641],"Preliminary":[644],"analysis":[645],"showed":[646],"correlation":[648],"on":[653,674],"peripheral":[654,704],"cells":[657,676],"clinical":[659,668],"response.":[660],"Further":[661],"explore":[664],"association":[666],"MM":[675],"within":[677],"BMAs":[678],"underway.":[680],"Conclusions":[681],"has":[684],"novel":[686],"mechanism":[687],"action,":[689],"manageable":[691],"profile,":[693],"encouraging":[695],"activity":[697],"independent":[702],"cell":[707],"expression.":[709],"A":[710],"randomized":[711],"compare":[716],"fixed-dose":[717],"120":[720],"240":[722],"(equivalent":[724],"3.0":[728],"mg/kg)":[729],"define":[733],"single-agent":[735],"optimal":[739],"benefit/risk":[740],"profile":[741],"currently":[743],"enrolling.":[744],"Figure":[745],"1View":[746,749],"largeDownload":[747,750],"PPTFigure":[748],"PPT":[751],"Close":[752],"modal":[753]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":6}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}